Skip to main content

Table 5 Weight management, blood glucose and blood lipids: Non-caloric versus Sucrose

From: A systematic review on the effect of sweeteners on glycemic response and clinically relevant outcomes

Non-caloric
sweetener
Population Timepoint (week) No of participants MD (95% CI)
BMI, kg/m2
Aspartame General 4 133 -0.3 (-1.1,0.5)
Mixturea Overweight 10 41 -0.9 (-1.5,-0.4)
Weight, kg
Cyclamate DM1 4 10 0.8 (-3.3,4.9)
Mixture Overweight 10 41 -2.6 (-3.7,-1.5)
Day Energy Intake, kcal
Aspartame General 4 133 -283 (-414,-153)
Mixture Overweight 10 41 -491 (-806,-177)
HbA1C, %
Cyclamate DM1 4 10 -0.02 (-0.4,0.3)
HOMA Index
Mixture Overweight 10 41 -0.20 (-0.58,0.18)
Total Cholesterol, mmol/L
Cyclamate DM1 4 10 -0.34 (-0.87,0.19)
HDL Cholesterol, mmol/L
Cyclamate DM1 4 10 -0.05 (-0.32,0.22)
Triglycerides, mmol/L
Cyclamate DM1 4 10 -0.02 (-0.16,0.12)
Mixture Overweight 10 41 -0.26 (-0.85,0.34)
  1. aAspartame, acesulfame, cyclamate, saccharin
  2. DM1, Type 1 Diabetes Mellitus; DM2, Type 2 Diabetes Mellitus; BMI, Body mass index; HbA1C, Glycated haemoglobin; HOMA, Homeostatic Model Assessment; MD, Mean difference; CI, Confidence interval
  3. Statistically significant results are bolded.